Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial

MLA

“Breztri Aerosphere Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial.” Plus Company Updates, 25 June 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.627668556&authtype=sso&custid=ns315887.

APA

Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial. (2020, June 25). Plus Company Updates.

Chicago

Plus Company Updates. 2020. “Breztri Aerosphere Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial,” June 25. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.627668556&authtype=sso&custid=ns315887.